$20 billion in cardiovascular drug revenues soon subject to patent expiration

More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next three to five years, according to a report by business intelligence firm Cutting Edge Information.

Continue to $20 billion in cardiovascular drug revenues soon subject to patent expiration on News-Medical News Feed.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz